REMEMBER-FX® clinical trials¹

A Pilot Study in Young and Middle Aged Healthy Adults
A trial was conducted to determine the effect on cognitive functions in two healthy groups of adults, a young age group (20 to 24 years of age) and a middle age group (45 to 65 years of age). Ten participants were recruited for each group and instructed to take 100 mg capsules of REMEMBER-FX twice daily for two weeks. Assessments were conducted using the Clinical Memory Scale consisting of 5 sets of memory tests. Following 2 weeks of treatment, the young age group demonstrated statistically significant improvements in 4 of 5 memory tests. For the middle age adult group, statistically significant changes were found in 3 of 5 tests. Results suggest that REMEMBER-FX has potential for improving learning and memory.²

Changes in memory quotients after two weeks of treatment with REMEMBER-FX.

A Placebo Controlled Trial in Persons with Schizophrenia
In a double-blind, placebo-controlled trial, 64 persons with Schizophrenia were randomly instructed to take 100 mg of REMEMBER-FX or placebo twice daily for a duration of 4 weeks. Participants completed two working memory tests at baseline and following treatment.  Working visual memory was found to be significantly improved in the REMEMBER-FX group compared with the placebo group. This study demonstrated improved visual working memory in persons with schizophrenia.³

Significant improvements observed for visual pattern testing following treatment with REMEMBER-FX in persons with schizophrenia for 4 weeks.

¹A clinical trial is a study conducted to evaluate a drug. Each study is designed to determine if promising new treatments are safe and effective for patients. By adhering to strict scientific guidelines during a clinical trial, a wealth of information is gained about a new drug, its risks, and effectiveness.

²Lai CT, Wang LJ, Liu GZ, Sutherland SK and Shan JJ. REMEMBER-FX (HT1001™) Improved Learning and Memory Functions in Young and Middle Age Healthy Adults: A Pilot Study. Abstract. Presented at the 2007 Canadian Collage of Neuropsychopharmacology Annual Meeting, Banff, AB, June 15-18, 2007 and the 4th Canadian Colloquium on Dementia, Vancouver, BC, October 18-20, 2007.